Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q1- Text added to 2022 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
academic, adjunctive, animal, Asia, authentic, Beta, blockage, blood, bring, cohort, combat, Conference, conferred, consortium, CoV, destruction, EFPIA, engineered, entry, Epsilon, Europe, fusion, Gamma, GCP, Harmonization, higher, host, ICH, IMI, inhibition, intramuscular, intranasal, JU, licensee, macaque, network, North, Omicron, prophylactic, prophylactically, receptor, referenced, role, secreting, shown, sponsor, strain, Subtopic, syndrome, test, tested, Union, vitro, widely, wildtype, Wuhan
Valuein 2022 Q1 filing- Value in 2022 Q2 filing
Original filings
Filing view